

REFERENCES

7 REFERENCES

1. DeFronzo, R. A., Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. *Diabetologia* **1992**, 35, (4), 389-397.
2. Ginsberg, H. N.; Zhang, Y.-L.; Hernandez-Ono, A., Metabolic Syndrome: Focus on Dyslipidemia. *Obesity* **2006**, 14, (S2), 41S-49S.
3. Adiels, M.; Olofsson, S.-O.; Taskinen, M.-R.; Borén, J., Diabetic dyslipidaemia. *Current Opinion in Lipidology* **2006**, 17, (3), 238-246.
4. Taskinen, M. R., Type 2 Diabetes as a Lipid Disorder. *Current Molecular Medicine* **2005**, 5, (3), 297-308.
5. Garvey, W. T.; Kwon, S.; Zheng, D.; Shaughnessy, S.; Wallace, P.; Hutto, A.; Pugh, K.; Jenkins, A. J.; Klein, R. L.; Liao, Y., Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance. *Diabetes* **2003**, 52, (2), 453-462.
6. Krentz, A. J., Lipoprotein abnormalities and their consequences for patients with Type 2 diabetes. *Diabetes, Obesity and Metabolism* **2003**, 5, s19-s27.
7. Solano, M. P.; Goldberg, R. B., Management of Dyslipidemia in Diabetes. *Cardiology in Review* **2006**, 14, (3), 125-135.
8. Goff Jr, D. C.; Gerstein, H. C.; Ginsberg, H. N.; Cushman, W. C.; Margolis, K. L.; Byington, R. P.; Buse, J. B.; Genuth, S.; Probstfield, J. L.; Simons-Morton, D. G., Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *The American Journal of Cardiology* **2007**, 99, (12, Supplement), S4-S20.
9. Adiels, M.; Olofsson, S.-O.; Taskinen, M.-R.; Borén, J., Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology* **2008**, 28, (7), 1225-1236.
10. Group, U. K. P. D. S., Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet* **1998**, 352, (9131), 837-853.
11. Stratton, I. M.; Adler, A. I.; Neil, H. A.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R. C.; Holman, R. R., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *Bmj* **2000**, 321, (7258), 405-12.
12. Group, U. K. P. D. S., U.K. Prospective Diabetes Study 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. *Diabetes Care* **1997**, 20, (11), 1683-1687.
13. Farmer, J. A., Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. *Curr Diab Rep* **2008**, 8, (1), 71-7.
14. Packard, C. J.; Shepherd, J., Lipoprotein heterogeneity and apolipoprotein B metabolism. *Arterioscler Thromb Vasc Biol* **1997**, 17, (12), 3542-56.
15. Berger, J. P.; Akiyama, T. E.; Meinke, P. T., PPARs: therapeutic targets for metabolic disease. *Trends in Pharmacological Sciences* **2005**, 26, (5), 244-251.

16. Wahli, W.; Braissant, O.; Desvergne, B., Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more.... *Chemistry & Biology* **1995**, 2, (5), 261-266.
17. Nuclear Receptors Nomenclature, C., A Unified Nomenclature System for the Nuclear Receptor Superfamily. *Cell* **1999**, 97, (2), 161-163.
18. Shearer, B. G.; Billin, A. N., The next generation of PPAR drugs: Do we have the tools to find them? *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **2007**, 1771, (8), 1082-1093.
19. Shao, D.; Rangwala, S. M.; Bailey, S. T.; Krakow, S. L.; Reginato, M. J.; Lazar, M. A., Interdomain communication regulating ligand binding by PPAR-[gamma]. *Nature* **1998**, 396, (6709), 377-380.
20. Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M., Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. *Nature* **1992**, 358, (6389), 771-774.
21. Berger, J.; Moller, D. E., The mechanisms of action of PPARs. *Annu Rev Med* **2002**, 53, 409-35.
22. Escher, P.; Wahli, W., Peroxisome proliferator-activated receptors: insight into multiple cellular functions. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis* **2000**, 448, (2), 121-138.
23. Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W., From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. *Progress in Lipid Research* **2006**, 45, (2), 120-159.
24. Bourguet, W.; Ruff, M.; Chambon, P.; Gronemeyer, H.; Moras, D., Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. *Nature* **1995**, 375, (6530), 377-82.
25. Renaud, J. P.; Rochel, N.; Ruff, M.; Vivat, V.; Chambon, P.; Gronemeyer, H.; Moras, D., Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. *Nature* **1995**, 378, (6558), 681-9.
26. Lu, I. L.; Huang, C.-F.; Peng, Y.-H.; Lin, Y.-T.; Hsieh, H.-P.; Chen, C.-T.; Lien, T.-W.; Lee, H.-J.; Mahindroo, N.; Prakash, E.; Yueh, A.; Chen, H.-Y.; Goparaju, C. M. V.; Chen, X.; Liao, C.-C.; Chao, Y.-S.; Hsu, J. T. A.; Wu, S.-Y., Structure-Based Drug Design of a Novel Family of PPAR γ Partial Agonists: Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities. *Journal of Medicinal Chemistry* **2006**, 49, (9), 2703-2712.
27. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Sternbach, D. D.; Lehmann, J. M.; Wisely, G. B.; Willson, T. M.; Kliewer, S. A.; Milburn, M. V., Molecular Recognition of Fatty Acids by Peroxisome Proliferator-Activated Receptors. *Molecular Cell* **1999**, 3, (3), 397-403.
28. Fyffe, S. A.; Alpey, M. S.; Buetow, L.; Smith, T. K.; Ferguson, M. A. J.; Sørensen, M. D.; Björkling, F.; Hunter, W. N., Recombinant Human PPAR- β/δ Ligand-binding Domain is Locked in an Activated Conformation by Endogenous Fatty Acids. *Journal of Molecular Biology* **2006**, 356, (4), 1005-1013.

29. Gampe Jr, R. T.; Montana, V. G.; Lambert, M. H.; Miller, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliewer, S. A.; Willson, T. M.; Xu, H. E., Asymmetry in the PPAR γ /RXR α Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. *Molecular Cell* **2000**, 5, (3), 545-555.
30. Li, Y.; Choi, M.; Suino, K.; Kovach, A.; Daugherty, J.; Kliewer, S. A.; Xu, H. E., Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. *Proceedings of the National Academy of Sciences of the United States of America* **2005**, 102, (27), 9505-9510.
31. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M., Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A* **2001**, 98, (24), 13919-24.
32. Ebdrup, S.; Pettersson, I.; Rasmussen, H. B.; Deussen, H. J.; Frost Jensen, A.; Mortensen, S. B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P., Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. *J Med Chem* **2003**, 46, (8), 1306-17.
33. A, I. J.; Jeannin, E.; Wahli, W.; Desvergne, B., Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. *J Biol Chem* **1997**, 272, (32), 20108-17.
34. Gearing, K. L.; Gottlicher, M.; Teboul, M.; Widmark, E.; Gustafsson, J. A., Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. *Proc Natl Acad Sci U S A* **1993**, 90, (4), 1440-4.
35. Juge-Aubry, C.; Pernin, A.; Favez, T.; Burger, A. G.; Wahli, W.; Meier, C. A.; Desvergne, B., DNA Binding Properties of Peroxisome Proliferator-activated Receptor Subtypes on Various Natural Peroxisome Proliferator Response Elements: IMPORTANCE OF THE 5'-FLANKING REGION. *Journal of Biological Chemistry* **1997**, 272, (40), 25252-25259.
36. Lemberger, T.; Desvergne, B.; Wahli, W., Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. *Annu Rev Cell Dev Biol* **1996**, 12, 335-63.
37. Chen, J. D.; Evans, R. M., A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* **1995**, 377, (6548), 454-457.
38. Horlein, A. J.; Naar, A. M.; Heinzl, T.; Torchia, J.; Gloss, B.; Kurokawa, R.; Ryan, A.; Kamei, Y.; Soderstrom, M.; Glass, C. K.; Rosenfeld, M. G., Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* **1995**, 377, (6548), 397-404.
39. Xu, L.; Glass, C. K.; Rosenfeld, M. G., Coactivator and corepressor complexes in nuclear receptor function. *Current Opinion in Genetics & Development* **1999**, 9, (2), 140-147.
40. Zhu, Y.; Qi, C.; Calandra, C.; Rao, M. S.; Reddy, J. K., Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. *Gene Expr* **1996**, 6, (3), 185-95.

41. Zhu, Y.; Qi, C.; Jain, S.; Rao, M. S.; Reddy, J. K., Isolation and Characterization of PBP, a Protein That Interacts with Peroxisome Proliferator-activated Receptor. *Journal of Biological Chemistry* **1997**, 272, (41), 25500-25506.
42. Sher, T.; Yi, H. F.; McBride, O. W.; Gonzalez, F. J., cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. *Biochemistry* **1993**, 32, (21), 5598-5604.
43. Auboeuf, D.; Rieusset, J.; Fajas, L.; Vallier, P.; Frering, V.; Riou, J. P.; Staels, B.; Auwerx, J.; Laville, M.; Vidal, H., Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor- α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients. *Diabetes* **1997**, 46, (8), 1319-1327.
44. Braissant, O.; Fougère, F.; Scotto, C.; Dauca, M.; Wahli, W., Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR- α , - β , and - γ in the adult rat. *Endocrinology* **1996**, 137, (1), 354-66.
45. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R., The PPARs: from orphan receptors to drug discovery. *J Med Chem* **2000**, 43, (4), 527-50.
46. Issemann, I.; Green, S., Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature* **1990**, 347, (6294), 645-650.
47. Cattley, R. C.; DeLuca, J.; Elcombe, C.; Fenner-Crisp, P.; Lake, B. G.; Marsman, D. S.; Pastoor, T. A.; Popp, J. A.; Robinson, D. E.; Schwetz, B.; Tugwood, J.; Wahli, W., Do Peroxisome Proliferating Compounds Pose a Hepatocarcinogenic Hazard to Humans? *Regulatory Toxicology and Pharmacology* **1998**, 27, (1), 47-60.
48. Palmer, C. N.; Hsu, M. H.; Griffin, K. J.; Raucy, J. L.; Johnson, E. F., Peroxisome proliferator activated receptor- α expression in human liver. *Mol Pharmacol* **1998**, 53, (1), 14-22.
49. Lambe, K. G.; Woodyatt, N. J.; Macdonald, N.; Chevalier, S.; Roberts, R. A., Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. *Toxicology Letters* **1999**, 110, (1-2), 119-127.
50. Fruchart, J.-C., Peroxisome proliferator-activated receptor- α activation and high-density lipoprotein metabolism. *The American Journal of Cardiology* **2001**, 88, (12, Supplement 1), 24-29.
51. Schoonjans, K.; Staels, B.; Auwerx, J., Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. *J Lipid Res* **1996**, 37, (5), 907-25.
52. Schoonjans, K.; Watanabe, M.; Suzuki, H.; Mahfoudi, A.; Krey, G.; Wahli, W.; Grimaldi, P.; Staels, B.; Yamamoto, T.; Auwerx, J., Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter. *Journal of Biological Chemistry* **1995**, 270, (33), 19269-19276.
53. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J. C., Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* **1998**, 98, (19), 2088-93.

54. Heller, F.; Harvengt, C., Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. *Eur J Clin Pharmacol* **1983**, 25, (1), 57-63.
55. Marx, N.; Sukhova, G. K.; Collins, T.; Libby, P.; Plutzky, J., PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. *Circulation* **1999**, 99, (24), 3125-31.
56. Thurberg, B. L.; Collins, T., The nuclear factor- κ B/inhibitor of kappa B autoregulatory system and atherosclerosis. *Current Opinion in Lipidology* **1998**, 9, (5), 387-396.
57. Delerive, P.; De Bosscher, K.; Besnard, S.; Vanden Berghe, W.; Peters, J. M.; Gonzalez, F. J.; Fruchart, J.-C.; Tedgui, A.; Haegeman, G.; Staels, B., Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF- κ B and AP-1. *Journal of Biological Chemistry* **1999**, 274, (45), 32048-32054.
58. Young-Ran, K.; Choong-Hwan, K.; Jin-Yong, H., Safety and Efficacy of Peroxisome Proliferator-Activated Receptor- α Agonist for Treating Cardiovascular Disease. *Korean Circ J.* **2007**, 37, 599-608.
59. Costet, P.; Legendre, C.; Moré, J.; Edgar, A.; Galtier, P.; Pineau, T., Peroxisome Proliferator-activated Receptor α -Isoform Deficiency Leads to Progressive Dyslipidemia with Sexually Dimorphic Obesity and Steatosis. *Journal of Biological Chemistry* **1998**, 273, (45), 29577-29585.
60. Gonzalez, F. J., Recent update on the PPAR α -null mouse. *Biochimie* **1997**, 79, (2-3), 139-144.
61. Alegret, M.; Cerqueda, E.; Ferrando, R.; Vazquez, M.; Sanchez, R. M.; Adzet, T.; Merlos, M.; Laguna, J. C., Selective modification of rat hepatic microsomal fatty acid chain elongation and desaturation by fibrates: relationship with peroxisome proliferation. *Br J Pharmacol* **1995**, 114, (7), 1351-8.
62. Alegret, M.; Ferrando, R.; Vazquez, M.; Adzet, T.; Merlos, M.; Laguna, J. C., Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. *Br J Pharmacol* **1994**, 112, (2), 551-6.
63. Vazquez, M.; Merlos, M.; Adzet, T.; Laguna, J. C., Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition. *Br J Pharmacol* **1996**, 117, (6), 1155-62.
64. Vazquez, M.; Munoz, S.; Alegret, M.; Adzet, T.; Merlos, M.; Laguna, J. C., Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats. *Br J Pharmacol* **1995**, 116, (3), 2067-75.
65. Torra, I. P.; Gervois, P.; Staels, B., Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. *Current Opinion in Lipidology* **1999**, 10, (2), 151-160.
66. Jacobsson, A.; Stadler, U.; Glotzer, M. A.; Kozak, L. P., Mitochondrial uncoupling protein from mouse brown fat. Molecular cloning, genetic mapping, and mRNA expression. *Journal of Biological Chemistry* **1985**, 260, (30), 16250-4.

67. Cabrero, À.; Llaverías, G.; Roglans, N.; Alegret, M.; Sánchez, R.; Adzet, T.; Laguna, J. C.; Vázquez, M., Uncoupling Protein-3 mRNA Levels Are Increased in White Adipose Tissue and Skeletal Muscle of Bezafibrate-Treated Rats. *Biochemical and Biophysical Research Communications* **1999**, 260, (2), 547-556.
68. Krook, A.; Digby, J.; O'Rahilly, S.; Zierath, J. R.; Wallberg-Henriksson, H., Uncoupling protein 3 is reduced in skeletal muscle of NIDDM patients. *Diabetes* **1998**, 47, (9), 1528-1531.
69. Brun, S.; Carmona, M. C.; Mampel, T.; Viñas, O.; Giralt, M.; Iglesias, R.; Villarroya, F., Activators of peroxisome proliferator-activated receptor- α induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth. *Diabetes* **1999**, 48, (6), 1217-1222.
70. Kliewer, S. A.; Forman, B. M.; Blumberg, B.; Ong, E. S.; Borgmeyer, U.; Mangelsdorf, D. J.; Umesono, K.; Evans, R. M., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A* **1994**, 91, (15), 7355-9.
71. Zhu, Y.; Alvares, K.; Huang, Q.; Rao, M. S.; Reddy, J. K., Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. *Journal of Biological Chemistry* **1993**, 268, (36), 26817-26820.
72. Aperlo, C.; Pognonec, P.; Saladin, R.; Auwerx, J.; Boulukos, K. E., cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor hPPAR γ . *Gene* **1995**, 162, (2), 297-302.
73. Hotta, K.; Gustafson, T. A.; Yoshioka, S.; Ortmeyer, H. K.; Bodkin, N. L.; Hansen, B. C., Relationships of PPAR γ and PPAR γ 2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys. *Int J Obes Relat Metab Disord* **1998**, 22, (10), 1000-10.
74. Elbrecht, A.; Chen, Y.; Cullinan, C. A.; Hayes, N.; Leibowitz, M. D.; Moller, D. E.; Berger, J., Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ 1 and γ 2. *Biochemical and Biophysical Research Communications* **1996**, 224, (2), 431-437.
75. Greene, M. E.; Blumberg, B.; McBride, O. W.; Yi, H. F.; Kronquist, K.; Kwan, K.; Hsieh, L.; Greene, G.; Nimer, S. D., Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. *Gene Expr* **1995**, 4, (4-5), 281-99.
76. Lambe, K. G.; Tugwood, J. D., A Human Peroxisome-Proliferator-Activated Receptor- γ is Activated by Inducers of Adipogenesis, Including Thiazolidinedione Drugs. *European Journal of Biochemistry* **1996**, 239, (1), 1-7.
77. Beamer, B. A.; Negri, C.; Yen, C.-J.; Gavrilo, O.; Rumberger, J. M.; Durcan, M. J.; Yarnall, D. P.; Hawkins, A. L.; Griffin, C. A.; Burns, D. K.; Roth, J.; Reitman, M.; Shuldiner, A. R., Chromosomal Localization and Partial Genomic Structure of the Human Peroxisome Proliferator Activated Receptor-Gamma (hPPAR γ) Gene. *Biochemical and Biophysical Research Communications* **1997**, 233, (3), 756-759.
78. Kubota, N.; Terauchi, Y.; Miki, H.; Tamemoto, H.; Yamauchi, T.; Komeda, K.; Satoh, S.; Nakano, R.; Ishii, C.; Sugiyama, T.; Eto, K.; Tsubamoto, Y.; Okuno, A.; Murakami, K.;

- Sekihara, H.; Hasegawa, G.; Naito, M.; Toyoshima, Y.; Tanaka, S.; Shiota, K.; Kitamura, T.; Fujita, T.; Ezaki, O.; Aizawa, S.; Nagai, R.; Tobe, K.; Kimura, S.; Kadowaki, T., PPAR γ Mediates High-Fat Diet-Induced Adipocyte Hypertrophy and Insulin Resistance. *Molecular Cell* **1999**, 4, (4), 597-609.
79. Rosen, E. D.; Sarraf, P.; Troy, A. E.; Bradwin, G.; Moore, K.; Milstone, D. S.; Spiegelman, B. M.; Mortensen, R. M., PPAR γ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro. *Molecular Cell* **1999**, 4, (4), 611-617.
80. Knouff, C.; Auwerx, J., Peroxisome Proliferator-Activated Receptor- γ Calls for Activation in Moderation: Lessons from Genetics and Pharmacology. *Endocrine Reviews* **2004**, 25, (6), 899-918.
81. Deeb, S. S.; Fajas, L.; Nemoto, M.; Pihlajamaki, J.; Mykkanen, L.; Kuusisto, J.; Laakso, M.; Fujimoto, W.; Auwerx, J., A Pro12Ala substitution in PPAR[γ]2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet* **1998**, 20, (3), 284-287.
82. Okuno, A.; Tamemoto, H.; Tobe, K.; Ueki, K.; Mori, Y.; Iwamoto, K.; Umesono, K.; Akanuma, Y.; Fujiwara, T.; Horikoshi, H.; Yazaki, Y.; Kadowaki, T., Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. *J Clin Invest* **1998**, 101, (6), 1354-61.
83. Tontonoz, P.; Hu, E.; Graves, R. A.; Budavari, A. I.; Spiegelman, B. M., mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. *Genes Dev* **1994**, 8, (10), 1224-34.
84. Tontonoz, P.; Hu, E.; Devine, J.; Beale, E. G.; Spiegelman, B. M., PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. *Mol Cell Biol* **1995**, 15, (1), 351-7.
85. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A. M.; Heyman, R. A.; Briggs, M.; Deeb, S.; Staels, B.; Auwerx, J., PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. *Embo J* **1996**, 15, (19), 5336-48.
86. Martin, G.; Schoonjans, K.; Lefebvre, A.-M.; Staels, B.; Auwerx, J., Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPAR α and PPAR γ Activators. *Journal of Biological Chemistry* **1997**, 272, (45), 28210-28217.
87. Sfeir, Z.; Ibrahimi, A.; Amri, E.; Grimaldi, P.; Abumrad, N., Regulation of FAT/CD36 gene expression: further evidence in support of a role of the protein in fatty acid binding/transport. *Prostaglandins Leukot Essent Fatty Acids* **1997**, 57, (1), 17-21.
88. Kelly, L. J.; Vicario, P. P.; Thompson, G. M.; Candelore, M. R.; Doebber, T. W.; Ventre, J.; Wu, M. S.; Meurer, R.; Forrest, M. J.; Conner, M. W.; Cascieri, M. A.; Moller, D. E., Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression. *Endocrinology* **1998**, 139, (12), 4920-4927.
89. De Vos, P.; Lefebvre, A. M.; Miller, S. G.; Guerre-Millo, M.; Wong, K.; Saladin, R.; Hamann, L. G.; Staels, B.; Briggs, M. R.; Auwerx, J., Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. *J Clin Invest* **1996**, 98, (4), 1004-9.

90. Kallen, C. B.; Lazar, M. A., Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. *Proc Natl Acad Sci U S A* **1996**, 93, (12), 5793-6.
91. Ragolia, L.; Begum, N., Protein phosphatase-1 and insulin action. *Mol Cell Biochem* **1998**, 182, (1-2), 49-58.
92. Rydén, M.; Dicker, A.; van Harmelen, V.; Hauner, H.; Brunnberg, M.; Perbeck, L.; Lönnqvist, F.; Arner, P., Mapping of Early Signaling Events in Tumor Necrosis Factor- α -mediated Lipolysis in Human Fat Cells. *Journal of Biological Chemistry* **2002**, 277, (2), 1085-1091.
93. Stephens, J. M.; Lee, J.; Pilch, P. F., Tumor Necrosis Factor- α -induced Insulin Resistance in 3T3-L1 Adipocytes Is Accompanied by a Loss of Insulin Receptor Substrate-1 and GLUT4 Expression without a Loss of Insulin Receptor-mediated Signal Transduction. *Journal of Biological Chemistry* **1997**, 272, (2), 971-976.
94. Zingarelli, B.; Sheehan, M.; Hake, P. W.; O'Connor, M.; Denenberg, A.; Cook, J. A., Peroxisome Proliferator Activator Receptor- γ Ligands, 15-Deoxy- Δ 12,14-Prostaglandin J2 and Ciglitazone, Reduce Systemic Inflammation in Polymicrobial Sepsis by Modulation of Signal Transduction Pathways. *The Journal of Immunology* **2003**, 171, (12), 6827-6837.
95. Ma, L.-J.; Mao, S.-L.; Taylor, K. L.; Kanjanabuch, T.; Guan, Y.; Zhang, Y.; Brown, N. J.; Swift, L. L.; McGuinness, O. P.; Wasserman, D. H.; Vaughan, D. E.; Fogo, A. B., Prevention of Obesity and Insulin Resistance in Mice Lacking Plasminogen Activator Inhibitor 1. *Diabetes* **2004**, 53, (2), 336-346.
96. Maeda, N.; Takahashi, M.; Funahashi, T.; Kihara, S.; Nishizawa, H.; Kishida, K.; Nagaretani, H.; Matsuda, M.; Komuro, R.; Ouchi, N.; Kuriyama, H.; Hotta, K.; Nakamura, T.; Shimomura, I.; Matsuzawa, Y., PPAR γ Ligands Increase Expression and Plasma Concentrations of Adiponectin, an Adipose-Derived Protein. *Diabetes* **2001**, 50, (9), 2094-2099.
97. Berg, A. H.; Combs, T. P.; Du, X.; Brownlee, M.; Scherer, P. E., The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat Med* **2001**, 7, (8), 947-953.
98. Fruebis, J.; Tsao, T. S.; Javorschi, S.; Ebbets-Reed, D.; Erickson, M. R.; Yen, F. T.; Bihain, B. E.; Lodish, H. F., Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. *Proc Natl Acad Sci U S A* **2001**, 98, (4), 2005-10.
99. Hotta, K.; Funahashi, T.; Arita, Y.; Takahashi, M.; Matsuda, M.; Okamoto, Y.; Iwahashi, H.; Kuriyama, H.; Ouchi, N.; Maeda, K.; Nishida, M.; Kihara, S.; Sakai, N.; Nakajima, T.; Hasegawa, K.; Muraguchi, M.; Ohmoto, Y.; Nakamura, T.; Yamashita, S.; Hanafusa, T.; Matsuzawa, Y., Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* **2000**, 20, (6), 1595-9.
100. Combs, T. P.; Wagner, J. A.; Berger, J.; Doebber, T.; Wang, W. J.; Zhang, B. B.; Tanen, M.; Berg, A. H.; O'Rahilly, S.; Savage, D. B.; Chatterjee, K.; Weiss, S.; Larson, P. J.; Gottesdiener, K. M.; Gertz, B. J.; Charron, M. J.; Scherer, P. E.; Moller, D. E., Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR γ agonists: a potential mechanism of insulin sensitization. *Endocrinology* **2002**, 143, (3), 998-1007.
101. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S., A transgenic model of visceral obesity and the metabolic syndrome. *Science* **2001**, 294, (5549), 2166-70.

102. Berger, J.; Tanen, M.; Elbrecht, A.; Hermanowski-Vosatka, A.; Moller, D. E.; Wright, S. D.; Thieringer, R., Peroxisome Proliferator-activated Receptor- γ Ligands Inhibit Adipocyte 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression and Activity. *Journal of Biological Chemistry* **2001**, 276, (16), 12629-12635.
103. Kersten, S., Peroxisome proliferator activated receptors and obesity. *European Journal of Pharmacology* **2002**, 440, (2-3), 223-234.
104. Kramer, D.; Shapiro, R.; Adler, A.; Bush, E.; Rondinone, C. M., Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. *Metabolism* **2001**, 50, (11), 1294-1300.
105. Baumann, C. A.; Chokshi, N.; Saltiel, A. R.; Ribon, V., Cloning and Characterization of a Functional Peroxisome Proliferator Activator Receptor- γ -responsive Element in the Promoter of the CAP Gene. *Journal of Biological Chemistry* **2000**, 275, (13), 9131-9135.
106. Bogacka, I.; Xie, H.; Bray, G. A.; Smith, S. R., The Effect of Pioglitazone on Peroxisome Proliferator-Activated Receptor- γ Target Genes Related to Lipid Storage In Vivo. *Diabetes Care* **2004**, 27, (7), 1660-1667.
107. Thirone, A. C. P.; Carvalheira, J. B. C.; Hirata, A. E.; Velloso, L. A.; Saad, M. J. A., Regulation of Cbl-Associated Protein/Cbl Pathway in Muscle and Adipose Tissues of Two Animal Models of Insulin Resistance. *Endocrinology* **2004**, 145, (1), 281-293.
108. SMITH, U.; GOGG, S.; JOHANSSON, A.; OLAUSSON, T.; ROTTER, V.; SVALSTEDT, B., Thiazolidinediones (PPAR γ agonists) but not PPAR α agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. *The FASEB Journal* **2001**, 15, (1), 215-220.
109. Rajala, M. W.; Scherer, P. E., Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology* **2003**, 144, (9), 3765-73.
110. Bajaj, M.; Suraamornkul, S.; Piper, P.; Hardies, L. J.; Glass, L.; Cersosimo, E.; Pratipanawatr, T.; Miyazaki, Y.; DeFronzo, R. A., Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. *J Clin Endocrinol Metab* **2004**, 89, (1), 200-6.
111. Yamauchi, T.; Kamon, J.; Waki, H.; Terauchi, Y.; Kubota, N.; Hara, K.; Mori, Y.; Ide, T.; Murakami, K.; Tsuboyama-Kasaoka, N.; Ezaki, O.; Akanuma, Y.; Gavrilova, O.; Vinson, C.; Reitman, M. L.; Kagechika, H.; Shudo, K.; Yoda, M.; Nakano, Y.; Tobe, K.; Nagai, R.; Kimura, S.; Tomita, M.; Froguel, P.; Kadowaki, T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat Med* **2001**, 7, (8), 941-946.
112. Way, J. M.; Harrington, W. W.; Brown, K. K.; Gottschalk, W. K.; Sundseth, S. S.; Mansfield, T. A.; Ramachandran, R. K.; Willson, T. M.; Kliewer, S. A., Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues. *Endocrinology* **2001**, 142, (3), 1269-1277.
113. Oakes, N. D.; Thalén, P. G.; Jacinto, S. M.; Ljung, B., Thiazolidinediones Increase Plasma-Adipose Tissue FFA Exchange Capacity and Enhance Insulin-Mediated Control of Systemic FFA Availability. *Diabetes* **2001**, 50, (5), 1158-1165.

114. Steppan, C. M.; Bailey, S. T.; Bhat, S.; Brown, E. J.; Banerjee, R. R.; Wright, C. M.; Patel, H. R.; Ahima, R. S.; Lazar, M. A., The hormone resistin links obesity to diabetes. *Nature* **2001**, 409, (6818), 307-312.
115. Ricote, M.; Huang, J.; Fajas, L.; Li, A.; Welch, J.; Najib, J.; Witztum, J. L.; Auwerx, J.; Palinski, W.; Glass, C. K., Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. *Proc Natl Acad Sci U S A* **1998**, 95, (13), 7614-9.
116. Chinetti, G.; Lestavel, S.; Bocher, V.; Remaley, A. T.; Neve, B.; Torra, I. P.; Teissier, E.; Minnich, A.; Jaye, M.; Duverger, N.; Brewer, H. B.; Fruchart, J.-C.; Clavey, V.; Staels, B., PPAR-[alpha] and PPAR-[gamma] activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nat Med* **2001**, 7, (1), 53-58.
117. Chawla, A.; Boisvert, W. A.; Lee, C.-H.; Laffitte, B. A.; Barak, Y.; Joseph, S. B.; Liao, D.; Nagy, L.; Edwards, P. A.; Curtiss, L. K.; Evans, R. M.; Tontonoz, P., A PPAR γ -LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis. *Molecular Cell* **2001**, 7, (1), 161-171.
118. Nagy, L.; Tontonoz, P.; Alvarez, J. G. A.; Chen, H.; Evans, R. M., Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPAR γ . *Cell* **1998**, 93, (2), 229-240.
119. Tontonoz, P.; Nagy, L.; Alvarez, J. G. A.; Thomazy, V. A.; Evans, R. M., PPAR γ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL. *Cell* **1998**, 93, (2), 241-252.
120. Ricote, M.; Li, A. C.; Willson, T. M.; Kelly, C. J.; Glass, C. K., The peroxisome proliferator-activated receptor-[gamma] is a negative regulator of macrophage activation. *Nature* **1998**, 391, (6662), 79-82.
121. Jiang, C.; Ting, A. T.; Seed, B., PPAR-[gamma] agonists inhibit production of monocyte inflammatory cytokines. *Nature* **1998**, 391, (6662), 82-86.
122. Murao, K.; Imachi, H.; Momoi, A.; Sayo, Y.; Hosokawa, H.; Sato, M.; Ishida, T.; Takahara, J., Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. *FEBS Letters* **1999**, 454, (1-2), 27-30.
123. Mohapatra, J.; Sharma, M.; Singh, S.; Chatterjee, A.; Swain, P.; Balaraman, R.; Patel, P. R.; Jain, M. R., Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice. *Pharmacology* **2009**, 84, (4), 203-10.
124. Hsueh, W. A.; Law, R. E., PPAR γ and Atherosclerosis: Effects on Cell Growth and Movement. *Arteriosclerosis, Thrombosis, and Vascular Biology* **2001**, 21, (12), 1891-1895.
125. Bruemmer, D.; Berger, J. P.; Liu, J.; Kintscher, U.; Wakino, S.; Fleck, E.; Moller, D. E.; Law, R. E., A non-thiazolidinedione partial peroxisome proliferator-activated receptor γ ligand inhibits vascular smooth muscle cell growth. *European Journal of Pharmacology* **2003**, 466, (3), 225-234.
126. Bruemmer, D.; Yin, F.; Liu, J.; Berger, J. P.; Kiyono, T.; Chen, J.; Fleck, E.; Herle, A. J. V.; Forman, B. M.; Law, R. E., Peroxisome Proliferator-Activated Receptor γ Inhibits Expression

- of Minichromosome Maintenance Proteins in Vascular Smooth Muscle Cells. *Molecular Endocrinology* **2003**, 17, (6), 1005-1018.
127. Bruemmer, D.; Yin, F.; Liu, J.; Berger, J. P.; Sakai, T.; Blaschke, F.; Fleck, E.; Van Herle, A. J.; Forman, B. M.; Law, R. E., Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor γ in Vascular Smooth Muscle Cells. *Circulation Research* **2003**, 93, (4), e38-e47.
 128. Pasceri, V.; Wu, H. D.; Willerson, J. T.; Yeh, E. T. H., Modulation of Vascular Inflammation In Vitro and In Vivo by Peroxisome Proliferator-Activated Receptor- γ Activators. *Circulation* **2000**, 101, (3), 235-238.
 129. Kato, K.; Satoh, H.; Endo, Y.; Yamada, D.; Midorikawa, S.; Sato, W.; Mizuno, K.; Fujita, T.; Tsukamoto, K.; Watanabe, T., Thiazolidinediones Down-Regulate Plasminogen Activator Inhibitor Type 1 Expression in Human Vascular Endothelial Cells: A Possible Role for PPAR γ in Endothelial Function. *Biochemical and Biophysical Research Communications* **1999**, 258, (2), 431-435.
 130. Libby, P.; Ridker, P. M.; Maseri, A., Inflammation and Atherosclerosis. *Circulation* **2002**, 105, (9), 1135-1143.
 131. Marx, N.; Froehlich, J.; Siam, L.; Ittner, J.; Wierse, G.; Schmidt, A.; Scharnagl, H.; Hombach, V.; Koenig, W., Antidiabetic PPAR γ -Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology* **2003**, 23, (2), 283-288.
 132. Sher, T.; Yi, H. F.; McBride, O. W.; Gonzalez, F. J., cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. *Biochemistry* **1993**, 32, (21), 5598-604.
 133. Oliver, W. R., Jr.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Winegar, D. A.; Sznajdman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliwer, S. A.; Hansen, B. C.; Willson, T. M., A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci U S A* **2001**, 98, (9), 5306-11.
 134. Dressel, U.; Allen, T. L.; Pippal, J. B.; Rohde, P. R.; Lau, P.; Muscat, G. E., The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. *Mol Endocrinol* **2003**, 17, (12), 2477-93.
 135. Sprecher, D. L.; Massien, C.; Pearce, G.; Billin, A. N.; Perlstein, I.; Willson, T. M.; Hassall, D. G.; Ancellin, N.; Patterson, S. D.; Lobe, D. C.; Johnson, T. G., Triglyceride:High-Density Lipoprotein Cholesterol Effects in Healthy Subjects Administered a Peroxisome Proliferator Activated Receptor δ Agonist. *Arteriosclerosis, Thrombosis, and Vascular Biology* **2007**, 27, (2), 359-365.
 136. van der Veen, J. N.; Kruit, J. K.; Havinga, R.; Baller, J. F. W.; Chimini, G.; Lestavel, S.; Staels, B.; Groot, P. H. E.; Groen, A. K.; Kuipers, F., Reduced cholesterol absorption upon PPAR δ activation coincides with decreased intestinal expression of NPC1L1. *Journal of Lipid Research* **2005**, 46, (3), 526-534.

137. Luquet, S.; Lopez-Soriano, J.; Holst, D.; Fredenrich, A.; Melki, J.; Rassoulzadegan, M.; Grimaldi, P. A., Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. *Faseb J* **2003**, *17*, (15), 2299-301.
138. Wang, Y. X.; Zhang, C. L.; Yu, R. T.; Cho, H. K.; Nelson, M. C.; Bayuga-Ocampo, C. R.; Ham, J.; Kang, H.; Evans, R. M., Regulation of muscle fiber type and running endurance by PPARdelta. *PLoS Biol* **2004**, *2*, (10), 24.
139. Wang, Y.-X.; Lee, C.-H.; Tjep, S.; Yu, R. T.; Ham, J.; Kang, H.; Evans, R. M., Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity. *Cell* **2003**, *113*, (2), 159-170.
140. Fröhlich, M.; Imhof, A.; Berg, G.; Hutchinson, W. L.; Pepys, M. B.; Boeing, H.; Muche, R.; Brenner, H.; Koenig, W., Association between C-reactive protein and features of the metabolic syndrome: a population-based study. *Diabetes Care* **2000**, *23*, (12), 1835-1839.
141. Choi, K. C.; Lee, S. Y.; Yoo, H. J.; Ryu, O. H.; Lee, K. W.; Kim, S. M.; Baik, S. H.; Choi, K. M., Effect of PPAR- δ agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. *Biochemical and Biophysical Research Communications* **2007**, *357*, (1), 62-67.
142. Lee, C. H.; Olson, P.; Hevener, A.; Mehl, I.; Chong, L. W.; Olefsky, J. M.; Gonzalez, F. J.; Ham, J.; Kang, H.; Peters, J. M.; Evans, R. M., PPARdelta regulates glucose metabolism and insulin sensitivity. *Proc Natl Acad Sci U S A* **2006**, *103*, (9), 3444-9.
143. Lee, C. H.; Chawla, A.; Urbiztondo, N.; Liao, D.; Boisvert, W. A.; Evans, R. M.; Curtiss, L. K., Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. *Science* **2003**, *302*, (5644), 453-7.
144. Barish, G. D.; Narkar, V. A.; Evans, R. M., PPAR delta: a dagger in the heart of the metabolic syndrome. *J Clin Invest* **2006**, *116*, (3), 590-7.
145. Göttlicher, M.; Widmark, E.; Li, Q.; Gustafsson, J. A., Fatty acids activate a chimera of the clofibrilic acid-activated receptor and the glucocorticoid receptor. *Proceedings of the National Academy of Sciences* **1992**, *89*, (10), 4653-4657.
146. Kliewer, S. A.; Sundseth, S. S.; Jones, S. A.; Brown, P. J.; Wisely, G. B.; Koble, C. S.; Devchand, P.; Wahli, W.; Willson, T. M.; Lenhard, J. M.; Lehmann, J. M., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. *Proc Natl Acad Sci U S A* **1997**, *94*, (9), 4318-23.
147. Krey, G.; Braissant, O.; L'Horset, F.; Kalkhoven, E.; Perroud, M.; Parker, M. G.; Wahli, W., Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay. *Molecular Endocrinology* **1997**, *11*, (6), 779-791.
148. Yu, K.; Bayona, W.; Kallen, C. B.; Harding, H. P.; Ravera, C. P.; McMahon, G.; Brown, M.; Lazar, M. A., Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids. *Journal of Biological Chemistry* **1995**, *270*, (41), 23975-23983.
149. Gaw, A.; Packard, C. J.; Shepherd, J., Fibrates. In *Principles and Treatment of Lipoprotein Disorders*, Schettler, G.; Habenicht, A. R., Eds. Springer Berlin Heidelberg: 1994; Vol. 109, pp 325-348.

150. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliewer, S. A.; Willson, T. M., A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR α agonist with potent lipid-lowering activity. *J Med Chem* **1999**, 42, (19), 3785-8.
151. Miyachi, H.; Nomura, M.; Tanase, T.; Suzuki, M.; Murakami, K.; Awano, K., Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha. *Bioorganic & Medicinal Chemistry Letters* **2002**, 12, (3), 333-335.
152. Miyachi, H.; Nomura, M.; Tanase, T.; Takahashi, Y.; Ide, T.; Tsunoda, M.; Murakami, K.; Awano, K., Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPAR α -selective activators. *Bioorganic & Medicinal Chemistry Letters* **2002**, 12, (1), 77-80.
153. Shi, G. Q.; Dropinski, J. F.; Zhang, Y.; Santini, C.; Sahoo, S. P.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Agrawal, A.; Alvaro, R.; Cai, T.-q.; Hernandez, M.; Wright, S. D.; Moller, D. E.; Heck, J. V.; Meinke, P. T., Novel 2,3-Dihydrobenzofuran-2-carboxylic Acids: Highly Potent and Subtype-Selective PPAR α Agonists with Potent Hypolipidemic Activity. *Journal of Medicinal Chemistry* **2005**, 48, (17), 5589-5599.
154. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.; Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.; Bensch, W. R.; Barr, R. J.; Osborne, J.; Montrose-Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B., Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor α Agonist. *Journal of Medicinal Chemistry* **2003**, 46, (24), 5121-5124.
155. Schäfer, S. A.; Hansen, B. C.; Völkl, A.; Fahimi, H. D.; Pill, J., Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR) α activator, in non-human primates. *Biochemical Pharmacology* **2004**, 68, (2), 239-251.
156. Kuwabara, K.; Murakami, K.; Todo, M.; Aoki, T.; Asaki, T.; Murai, M.; Yano, J., A Novel Selective Peroxisome Proliferator-Activated Receptor α Agonist, 2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), Potently Decreases Plasma Triglyceride and Glucose Levels and Modifies Lipoprotein Profiles in KK-Ay Mice. *Journal of Pharmacology and Experimental Therapeutics* **2004**, 309, (3 Content-Disposition: inline; filename=endnote-citations.enw Via: 1.1 varnish), 970-977.
157. Frederick, K. S.; Maurer, T. S.; Kalgutkar, A. S.; Royer, L. J.; Francone, O. L.; Winter, S. M.; Terra, S. G.; Chen, D.; Gao, X., Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. *Xenobiotica* **2009**, 39, (10), 766-81.
158. Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Cap, M.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweiko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T. W., Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious

- Glucose and Lipid-Lowering Activities. *Journal of Medicinal Chemistry* **2005**, 48, (6), 2248-2250.
159. Li, J.; Kennedy, L. J.; Shi, Y.; Tao, S.; Ye, X.-Y.; Chen, S. Y.; Wang, Y.; Hernández, A. S.; Wang, W.; Devasthale, P. V.; Chen, S.; Lai, Z.; Zhang, H.; Wu, S.; Smirk, R. A.; Bolton, S. A.; Ryono, D. E.; Zhang, H.; Lim, N.-K.; Chen, B.-C.; Locke, K. T.; O'Malley, K. M.; Zhang, L.; Srivastava, R. A.; Miao, B.; Meyers, D. S.; Monshizadegan, H.; Search, D.; Grimm, D.; Zhang, R.; Harrity, T.; Kunselman, L. K.; Cap, M.; Kadiyala, P.; Hosagrahara, V.; Zhang, L.; Xu, C.; Li, Y.-X.; Muckelbauer, J. K.; Chang, C.; An, Y.; Krystek, S. R.; Blonar, M. A.; Zahler, R.; Mukherjee, R.; Cheng, P. T. W.; Tino, J. A., Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453). *Journal of Medicinal Chemistry* **2010**, 53, (7), 2854-2864.
160. Ye, X.-Y.; Chen, S.; Zhang, H.; Locke, K. T.; O'Malley, K.; Zhang, L.; Srivastava, R.; Miao, B.; Meyers, D.; Monshizadegan, H.; Search, D.; Grimm, D.; Zhang, R.; Lippy, J.; Twamley, C.; Muckelbauer, J. K.; Chang, C.; An, Y.; Hosagrahara, V.; Zhang, L.; Yang, T. J.; Mukherjee, R.; Cheng, P. T. W.; Tino, J. A., Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPAR α selective activators- PPAR α and PPAR γ selectivity modulation. *Bioorganic & Medicinal Chemistry Letters* **2010**, 20, (9), 2933-2937.
161. Wagner, J. D.; Shadoan, M. K.; Zhang, L.; Ward, G. M.; Royer, L. J.; Kavanagh, K.; Francone, O. L.; Auerbach, B. J.; Harwood, H. J., A Selective Peroxisome Proliferator-Activated Receptor α Agonist, CP-900691, Improves Plasma Lipids, Lipoproteins, and Glycemic Control in Diabetic Monkeys. *Journal of Pharmacology and Experimental Therapeutics* **2010**, 333, (3), 844-853.
162. Nomura, M.; Yumoto, K.; Shinozaki, T.; Isogai, S.; Takano, Y.; Murakami, K., Discovery of cyclic amine-substituted benzoic acids as PPAR α agonists. *Bioorganic & Medicinal Chemistry Letters* **2012**, 22, (1), 334-338.
163. Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H., Design, Synthesis, and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Human Peroxisome Proliferator Activated Receptor Activators. Discovery of Potent and Human Peroxisome Proliferator Activated Receptor α Subtype-Selective Activators. *Journal of Medicinal Chemistry* **2003**, 46, (17), 3581-3599.
164. Kawamatsu, Y.; Asakawa, H.; Saraie, T.; Mizuno, K.; Imamiya, E.; Nishikawa, K.; Hamuro, Y., Studies on antihyperlipidemic agents. III. Synthesis and biological activities of 2-chloro-3-arylpropionic acids containing a quarternary carbon atom. *Arzneimittelforschung* **1980**, 30, (5), 751-8.
165. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y., Studies on antidiabetic agents. I. Synthesis of 5-[4-(2-methyl-2-phenylpropoxy)-benzyl]thiazolidine-2,4-dione (AL-321) and related compounds. *Chem Pharm Bull* **1982**, 30, (10), 3563-73.
166. Chang, A. Y.; Wyse, B. M.; Gilchrist, B. J.; Peterson, T.; Diani, A. R., Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats. *Diabetes* **1983**, 32, (9), 830-838.
167. Fujita, T.; Sugiyama, Y.; Taketomi, S.; Sohda, T.; Kawamatsu, Y.; Iwatsuka, H.; Suzuoki, Z., Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-

- Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent. *Diabetes* **1983**, 32, (9), 804-810.
168. Sohda, T.; Mizuno, K.; Imamiya, E.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y., Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. *Chem Pharm Bull* **1982**, 30, (10), 3580-600.
169. Sohda, T.; Kawamatsu, Y.; Fujita, T.; Meguro, K.; Ikeda, H., [Discovery and development of a new insulin sensitizing agent, pioglitazone]. *Yakugaku Zasshi* **2002**, 122, (11), 909-18.
170. Sohda, T.; Mizuno, K.; Momose, Y.; Ikeda, H.; Fujita, T.; Meguro, K., Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents. *J Med Chem* **1992**, 35, (14), 2617-26.
171. Azen, S. P.; Peters, R. K.; Berkowitz, K.; Kjos, S.; Xiang, A.; Buchanan, T. A., TRIPOD (Troglitazone In the Prevention Of Diabetes): A Randomized, Placebo-Controlled Trial of Troglitazone in Women with Prior Gestational Diabetes Mellitus. *Controlled Clinical Trials* **1998**, 19, (2), 217-231.
172. Iwamoto, Y.; Kosaka, K.; Kuzuya, T.; Akanuma, Y.; Shigeta, Y.; Kaneko, T., Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. *Diabetes Care* **1996**, 19, (2), 151-6.
173. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A., An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPAR γ). *Journal of Biological Chemistry* **1995**, 270, (22), 12953-12956.
174. Clark, D. A.; Goldstein, S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; et al., Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. *J Med Chem* **1991**, 34, (1), 319-25.
175. Gale, E. A. M., Lessons from the glitazones: a story of drug development. *The Lancet* **2001**, 357, (9271), 1870-1875.
176. Aronoff, S.; Rosenblatt, S.; Braithwaite, S.; Egan, J. W.; Mathisen, A. L.; Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. *Diabetes Care* **2000**, 23, (11), 1605-1611.
177. Phillips, L. S.; Grunberger, G.; Miller, E.; Patwardhan, R.; Rappaport, E. B.; Salzman, A., Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 Diabetes. *Diabetes Care* **2001**, 24, (2), 308-315.
178. Rosenblatt, S.; Miskin, B.; Glazer, N. B.; Prince, M. J.; Robertson, K. E.; Group, t. P. S., The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. *Coronary Artery Disease* **2001**, 12, (5), 413-423.
179. Wagstaff, A. J.; Goa, K. L., Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. *Drugs* **2002**, 62, (12), 1805-37.
180. Schimke, K.; Davis, T. M., Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. *Curr Opin Investig Drugs* **2007**, 8, (4), 338-44.
181. Rybczynski, P. J.; Zeck, R. E.; Dudash, J.; Combs, D. W.; Burris, T. P.; Yang, M.; Osborne, M. C.; Chen, X.; Demarest, K. T., Benzoxazinones as PPAR γ Agonists. 2. SAR of the Amide

- Substituent and In Vivo Results in a Type 2 Diabetes Model. *Journal of Medicinal Chemistry* **2004**, 47, (1), 196-209.
182. Rikimaru, K.; Wakabayashi, T.; Abe, H.; Imoto, H.; Maekawa, T.; Ujikawa, O.; Murase, K.; Matsuo, T.; Matsumoto, M.; Nomura, C.; Tsuge, H.; Arimura, N.; Kawakami, K.; Sakamoto, J.; Funami, M.; Mol, C. D.; Snell, G. P.; Bragstad, K. A.; Sang, B.-C.; Dougan, D. R.; Tanaka, T.; Katayama, N.; Horiguchi, Y.; Momose, Y., A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: Design and synthesis of benzylpyrazole acylsulfonamides. *Bioorganic & Medicinal Chemistry* **2012**, 20, (2), 714-733.
183. Forman, B. M.; Chen, J.; Evans, R. M., Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. *Proc Natl Acad Sci U S A* **1997**, 94, (9), 4312-7.
184. Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M. S.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E., Novel Peroxisome Proliferator-activated Receptor (PPAR) γ and PPAR δ Ligands Produce Distinct Biological Effects. *Journal of Biological Chemistry* **1999**, 274, (10), 6718-6725.
185. Sznajdman, M. L.; Haffner, C. D.; Maloney, P. R.; Fivush, A.; Chao, E.; Goreham, D.; Sierra, M. L.; LeGrumelec, C.; Xu, H. E.; Montana, V. G.; Lambert, M. H.; Willson, T. M.; Oliver Jr, W. R.; Sternbach, D. D., Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPAR δ)—synthesis and biological activity. *Bioorganic & Medicinal Chemistry Letters* **2003**, 13, (9), 1517-1521.
186. Weigand, S.; Bischoff, H.; Dittrich-Wengenroth, E.; Heckroth, H.; Lang, D.; Vaupel, A.; Woltering, M., Minor structural modifications convert a selective PPAR α agonist into a potent, highly selective PPAR δ agonist. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15, (20), 4619-4623.
187. Mausumee, G.; Mark, D.; James, M.; Kabakibi, A.; Guy, O.; Tadimetri, R., Abstract 3921: KD3010, a PPAR β/δ Selective Small Molecule Agonist, Improves Hyperglycemia And Insulin Resistance while alleviating Rosiglitazone-Induced Side Effects in Murine Models. *Circulation* **2006**, 114, II_843.
188. Choi, Y.-J.; Roberts, B. K.; Wang, X.; Geaney, J. C.; Naim, S.; Wojnoonski, K.; Karpf, D. B.; Krauss, R. M., Effects of the PPAR- δ agonist MBX-8025 on atherogenic dyslipidemia. *Atherosclerosis* **2012**, 220, (2), 470-476.
189. Luckhurst, C. A.; Stein, L. A.; Furber, M.; Webb, N.; Ratcliffe, M. J.; Allenby, G.; Botterell, S.; Tomlinson, W.; Martin, B.; Walding, A., Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPAR δ agonists. *Bioorganic & Medicinal Chemistry Letters* **2011**, 21, (1), 492-496.
190. Seber, S.; Ucak, S.; Basat, O.; Altuntas, Y., The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. *Diabetes Research and Clinical Practice* **2006**, 71, (1), 52-58.
191. Murakami, K.; Tobe, K.; Ide, T.; Mochizuki, T.; Ohashi, M.; Akanuma, Y.; Yazaki, Y.; Kadowaki, T., A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation

- on abnormal lipid metabolism in liver of Zucker fatty rats. *Diabetes* **1998**, 47, (12), 1841-1847.
192. Nissen, S. E.; Wolski, K.; Topol, E. J., Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. *JAMA* **2005**, 294, (20), 2581-2586.
193. Fagerberg, B.; Edwards, S.; Halmos, T.; Lopatynski, J.; Schuster, H.; Stender, S.; Stoa-Birketvedt, G.; Tonstad, S.; Halldórsdóttir, S.; Gause-Nilsson, I., Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. *Diabetologia* **2005**, 48, (9), 1716-1725.
194. Lohray, B. B.; Lohray, V. B.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadithyan, R. K.; Misra, P.; Juluri, S.; Mamidi, N. V. S. R.; Rajagopalan, R., (-)-3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(-)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity. *Journal of Medicinal Chemistry* **2001**, 44, (16), 2675-2678.
195. Martín, J. A.; Brooks, D. A.; Prieto, L.; González, R.; Torrado, A.; Rojo, I.; López de Uralde, B.; Lamas, C.; Ferritto, R.; Dolores Martín-Ortega, M.; Agejas, J.; Parra, F.; Rizzo, J. R.; Rhodes, G. A.; Robey, R. L.; Alt, C. A.; Wendel, S. R.; Zhang, T. Y.; Reifel-Miller, A.; Montrose-Rafizadeh, C.; Brozinick, J. T.; Hawkins, E.; Misener, E. A.; Briere, D. A.; Ardecky, R.; Fraser, J. D.; Warshawsky, A. M., 2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15, (1), 51-55.
196. Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A.; Noble, S. A.; Oliver, W.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M., N-(2-Benzoylphenyl)-l-tyrosine PPAR γ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. *Journal of Medicinal Chemistry* **1998**, 41, (25), 5020-5036.
197. Imoto, H.; Matsumoto, M.; Odaka, H.; Sakamoto, J.; Kimura, H.; Nonaka, M.; Kiyota, Y.; Momose, Y., Studies on non-thiazolidinedione antidiabetic agents. 3. Preparation and biological activity of the metabolites of TAK-559. *Chem Pharm Bull* **2004**, 52, (1), 120-4.
198. Li, P.-P.; Shan, S.; Chen, Y.-T.; Ning, Z.-Q.; Sun, S.-J.; Liu, Q.; Lu, X.-P.; Xie, M.-Z.; Shen, Z.-F., The PPAR α/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. *British Journal of Pharmacology* **2006**, 148, (5), 610-618.
199. Lu, Y.; Guo, Z.; Guo, Y.; Feng, J.; Chu, F., Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists. *Bioorganic & Medicinal Chemistry Letters* **2006**, 16, (4), 915-919.
200. Chen, H.; Dardik, B.; Qiu, L.; Ren, X.; Caplan, S. L.; Burkey, B.; Boettcher, B. R.; Gromada, J., Cevoglitazar, a Novel Peroxisome Proliferator-Activated Receptor- α/γ Dual Agonist, Potently Reduces Food Intake and Body Weight in Obese Mice and Cynomolgus Monkeys. *Endocrinology* **2010**, 151, (7), 3115-3124.

201. Shi, G. Q.; Dropinski, J. F.; McKeever, B. M.; Xu, S.; Becker, J. W.; Berger, J. P.; MacNaul, K. L.; Elbrecht, A.; Zhou, G.; Doebber, T. W.; Wang, P.; Chao, Y.-S.; Forrest, M.; Heck, J. V.; Moller, D. E.; Jones, A. B., Design and Synthesis of α -Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPAR α / γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity. *Journal of Medicinal Chemistry* **2005**, 48, (13), 4457-4468.
202. Colca, J. R., Discontinued drugs in 2008: endocrine and metabolic. *Expert Opin Investig Drugs* **2009**, 18, (9), 1243-55.
203. Chakrabarti, R.; Misra, P.; Vikramadithyan, R. K.; Premkumar, M.; Hiriyan, J.; Datla, S. R.; Damarla, R. K.; Suresh, J.; Rajagopalan, R., Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. *Eur J Pharmacol* **2004**, 491, (2-3), 195-206.
204. Hu, X.; Feng, Y.; Shen, Y.; Zhao, X. F.; Yu, J. H.; Yang, Y. S.; Leng, Y., Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. *Acta Pharmacol Sin* **2006**, 27, (10), 1346-52.
205. Jain, M. R.; Giri, S. R.; Trivedi, C.; Bhoi, B.; Rath, A.; Vanage, G.; Vyas, P.; Ranvir, R.; Patel, P. R., Saroglitazar, a novel PPARalpha/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. *Pharmacol Res Perspect* **2015**, 3, (3), 4.
206. Bénardeau, A.; Benz, J.; Binggeli, A.; Blum, D.; Boehringer, M.; Grether, U.; Hilpert, H.; Kuhn, B.; Märki, H. P.; Meyer, M.; Püntener, K.; Raab, S.; Ruf, A.; Schlatter, D.; Mohr, P., Aleglitazar, a new, potent, and balanced dual PPAR α / γ agonist for the treatment of type II diabetes. *Bioorganic & Medicinal Chemistry Letters* **2009**, 19, (9), 2468-2473.
207. Hansen, B. C.; Tigno, X. T.; Benardeau, A.; Meyer, M.; Sebokova, E.; Mizrahi, J., Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor alpha/gamma agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. *Cardiovasc Diabetol* **2011**, 10, (7), 1475-2840.
208. Balakumar, P.; Rose, M.; Ganti, S. S.; Krishan, P.; Singh, M., PPAR dual agonists: Are they opening Pandora's Box? *Pharmacological Research* **2007**, 56, (2), 91-98.
209. Fiévet, C.; Fruchart, J.-C.; Staels, B., PPAR α and PPAR γ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. *Current Opinion in Pharmacology* **2006**, 6, (6), 606-614.
210. Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J.-C.; Staels, B., Safety issues and prospects for future generations of PPAR modulators. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **2007**, 1771, (8), 1065-1081.
211. Boden, G.; Zhang, M., Recent findings concerning thiazolidinediones in the treatment of diabetes. *Expert Opin Investig Drugs* **2006**, 15, (3), 243-50.
212. Tenenbaum, A.; Motro, M.; Fisman, E. Z., Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. *Cardiovasc Diabetol* **2005**, 4, 14.
213. Evans, J. L.; Lin, J. J.; Goldfine, I. D., Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. *Curr Diabetes Rev* **2005**, 1, (3), 299-307.

214. Larsen, P. J.; Lykkegaard, K.; Larsen, L. K.; Fleckner, J.; Sauerberg, P.; Wassermann, K.; Wulff, E. M., Dissociation of antihyperglycaemic and adverse effects of partial peroxisome proliferator-activated receptor (PPAR- γ) agonist balaglitazone. *European Journal of Pharmacology* **2008**, 596, (1–3), 173-179.
215. Misra, P.; Chakrabarti, R.; Vikramadithyan, R. K.; Bolusu, G.; Juluri, S.; Hiriyani, J.; Gershome, C.; Rajjak, A.; Kashireddy, P.; Yu, S.; Surapureddi, S.; Qi, C.; Zhu, Y.-J.; Rao, M. S.; Reddy, J. K.; Ramanujam, R., PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic. *Journal of Pharmacology and Experimental Therapeutics* **2003**, 306, (2), 763-771.
216. Upton, R.; Widdowson, P. S.; Ishii, S.; Tanaka, H.; Williams, G., Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. *British Journal of Pharmacology* **1998**, 125, (8), 1708-1714.
217. Fukui, Y.; Masui, S.; Osada, S.; Umesono, K.; Motojima, K., A new thiazolidinedione, NC-2100, which is a weak PPAR- γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAY obese mice. *Diabetes* **2000**, 49, (5), 759-767.
218. Kim, J.; Han, D. C.; Kim, J. M.; Lee, S. Y.; Kim, S. J.; Woo, J. R.; Lee, J. W.; Jung, S. K.; Yoon, K. S.; Cheon, H. G.; Kim, S. S.; Hong, S. H.; Kwon, B. M., PPAR γ partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK. *Cellular and Molecular Life Sciences* **2009**, 66, (10), 1766-1781.
219. Li, Y.; Wang, Z.; Furukawa, N.; Escaron, P.; Weiszmann, J.; Lee, G.; Lindstrom, M.; Liu, J.; Liu, X.; Xu, H.; Plotnikova, O.; Prasad, V.; Walker, N.; Learned, R. M.; Chen, J.-L., T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor γ Binding Properties. *Journal of Biological Chemistry* **2008**, 283, (14), 9168-9176.
220. Sauerberg, P.; Olsen, G. S.; Jeppesen, L.; Mogensen, J. P.; Pettersson, I.; Jeppesen, C. B.; Daugaard, J. R.; Galsgaard, E. D.; Ynddal, L.; Fleckner, J.; Panajotova, V.; Polivka, Z.; Pihera, P.; Havranek, M.; Wulff, E. M., Identification and Synthesis of a Novel Selective Partial PPAR δ Agonist with Full Efficacy on Lipid Metabolism In Vitro and In Vivo. *Journal of Medicinal Chemistry* **2007**, 50, (7), 1495-1503.
221. Shearer, B. G.; Patel, H. S.; Billin, A. N.; Way, J. M.; Winegar, D. A.; Lambert, M. H.; Xu, R. X.; Leesnitzer, L. M.; Merrihew, R. V.; Huet, S.; Willson, T. M., Discovery of a novel class of PPAR δ partial agonists. *Bioorganic & Medicinal Chemistry Letters* **2008**, 18, (18), 5018-5022.
222. Fruchart, J.-C.; Duriez, P.; Staels, B., Peroxisome proliferator-activated receptor- α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. *Current Opinion in Lipidology* **1999**, 10, (3), 245-258.
223. Pourcet, B.; Fruchart, J. C.; Staels, B.; Glineur, C., Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis. *Expert Opin Emerg Drugs* **2006**, 11, (3), 379-401.
224. Elisaf, M., Effects of fibrates on serum metabolic parameters. *Curr Med Res Opin* **2002**, 18, (5), 269-76.

225. Pingali, H.; Jain, M.; Shah, S.; Makadia, P.; Zaware, P.; Goel, A.; Patel, M.; Giri, S.; Patel, H.; Patel, P., Design and synthesis of novel oxazole containing 1,3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. *Bioorganic & Medicinal Chemistry* **2008**, *16*, (15), 7117-7127.
226. Asaki, T.; Aoki, T.; Hamamoto, T.; Sugiyama, Y.; Ohmachi, S.; Kuwabara, K.; Murakami, K.; Todo, M., Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPAR α) agonists. *Bioorganic & Medicinal Chemistry* **2008**, *16*, (2), 981-994.
227. Sierra, M. L.; Beneton, V.; Boullay, A.-B.; Boyer, T.; Brewster, A. G.; Donche, F.; Forest, M.-C.; Fouchet, M.-H.; Gellibert, F. J.; Grillot, D. A.; Lambert, M. H.; Laroze, A.; Le Grumelec, C.; Linget, J. M.; Montana, V. G.; Nguyen, V.-L.; Nicodème, E.; Patel, V.; Penfornis, A.; Pineau, O.; Pohin, D.; Potvain, F.; Poulain, G.; Ruault, C. B.; Saunders, M.; Toum, J.; Xu, H. E.; Xu, R. X.; Pianetti, P. M., Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPAR α Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents. *Journal of Medicinal Chemistry* **2007**, *50*, (4), 685-695.
228. Pingali, H.; Jain, M.; Shah, S.; Makadia, P.; Zaware, P.; Jamili, J.; Sairam, K. V. V. M.; Patil, P.; Suthar, D.; Giri, S.; Patel, H.; Patel, P., Design and synthesis of novel 1, 3-dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. *Letters in Drug Design and Discovery* **2010**, *7*, (6), 421-429.
229. Rosenson, R. S.; Wright, R. S.; Farkouh, M.; Plutzky, J., Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. *American Heart Journal* **2012**, *164*, (5), 672-680.
230. Yamaguchi, M.; Shibata, Y.; Ohta, M.; Kagechika, K.; Usui, H.; Ohta, T., Novel zwitterionic phenoxyacetic acid derivatives as potent PPAR agonists, 234 th ACS Natl Meet. Abs MEDI 161. **2007**.
231. Sorbera, L. A.; Castaner, J.; del Fresno, M.; Silvestre, J., Netoglitazone. *Drugs of the Future* **2002**, *27*, (2), 132-139.
232. Imoto, H.; Sugiyama, Y.; Kimura, H.; Momose, Y., Studies on non-thiazolidinedione antidiabetic agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. *Chem Pharm Bull* **2003**, *51*, (2), 138-51.
233. Ljung, B.; Bamberg, K.; Dahllöf, B.; Kjellstedt, A.; Oakes, N. D.; Östling, J.; Svensson, L.; Camejo, G., AZ 242, a novel PPAR α/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. *Journal of Lipid Research* **2002**, *43*, (11), 1855-1863.
234. Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Rao, P. B.; Reddy, N. J.; Harikishore, P.; Haritha, N.; Vikramadityan, R. K.; Chakrabarti, R.; Rajagopalan, R.; Katneni, K., Novel Euglycemic and Hypolipidemic Agents. 4. Pyridyl- and Quinolinyl-Containing Thiazolidinediones. *Journal of Medicinal Chemistry* **1999**, *42*, (14), 2569-2581.
235. Pingali, H.; Jain, M.; Shah, S.; Basu, S.; Makadia, P.; Goswami, A.; Zaware, P.; Patil, P.; Godha, A.; Giri, S.; Goel, A.; Patel, M.; Patel, H.; Patel, P., Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. *Bioorganic & Medicinal Chemistry Letters* **2008**, *18*, (20), 5586-5590.

236. Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Reddy, A. S.; Kishore, P. H.; Rao, V. V.; Saibaba, V.; Bajji, A. C.; Rajesh, B. M.; Reddy, K. V.; Chakrabarti, R.; Rajagopalan, R., Novel euglycemic and hypolipidemic agents: Part - 2 antioxidant moiety as structural motif. *Bioorganic & Medicinal Chemistry Letters* **1998**, 8, (9), 999-1002.
237. Pingali, H.; Jain, M.; Shah, S.; Zaware, P.; Makadia, P.; Pola, S.; Thube, B.; Patel, D.; Patil, P.; Priyadarshini, P.; Suthar, D.; Shah, M.; Giri, S.; Patel, P., Design and synthesis of novel bis-oximinoalkanoic acids as potent PPAR α agonists. *Bioorganic & Medicinal Chemistry Letters* **2010**, 20, (3), 1156-1161.
238. Yanagisawa, H.; Takamura, M.; Yamada, E.; Fujita, S.; Fujiwara, T.; Yachi, M.; Isobe, A.; Hagiwara, Y., Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. *Bioorganic & Medicinal Chemistry Letters* **2000**, 10, (4), 373-375.
239. Pingali, H.; Jain, M.; Shah, S.; Patil, P.; Makadia, P.; Zaware, P.; Sairam, K. V. V. M.; Jamili, J.; Goel, A.; Patel, M.; Patel, P., Modulation of PPAR receptor subtype selectivity of the ligands: Aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. *Bioorganic & Medicinal Chemistry Letters* **2008**, 18, (24), 6471-6475.
240. Zoete, V.; Grosdidier, A.; Michelin, O., Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids* **2007**, 1771, (8), 915-925.
241. Acton III, J. J.; Black, R. M.; Jones, A. B.; Moller, D. E.; Colwell, L.; Doebber, T. W.; MacNaul, K. L.; Berger, J.; Wood, H. B., Benzoyl 2-methyl indoles as selective PPAR γ modulators. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15, (2), 357-362.
242. Dropinski, J. F.; Akiyama, T.; Einstein, M.; Habulihaz, B.; Doebber, T.; Berger, J. P.; Meinke, P. T.; Shi, G. Q., Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPAR γ partial agonists. *Bioorganic & Medicinal Chemistry Letters* **2005**, 15, (22), 5035-5038.
243. Hopkins, C. R.; O'Neil, S. V.; Laufersweiler, M. C.; Wang, Y.; Pokross, M.; Mekel, M.; Evdokimov, A.; Walter, R.; Kontoyianni, M.; Petrey, M. E.; Sabatakos, G.; Roesgen, J. T.; Richardson, E.; Demuth Jr, T. P., Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR- γ binding agents with potential application to the treatment of osteoporosis. *Bioorganic & Medicinal Chemistry Letters* **2006**, 16, (21), 5659-5663.
244. Mahindroo, N.; Huang, C.-F.; Peng, Y.-H.; Wang, C.-C.; Liao, C.-C.; Lien, T.-W.; Chittimalla, S. K.; Huang, W.-J.; Chai, C.-H.; Prakash, E.; Chen, C.-P.; Hsu, T.-A.; Peng, C.-H.; Lu, I. L.; Lee, L.-H.; Chang, Y.-W.; Chen, W.-C.; Chou, Y.-C.; Chen, C.-T.; Goparaju, C. M. V.; Chen, Y.-S.; Lan, S.-J.; Yu, M.-C.; Chen, X.; Chao, Y.-S.; Wu, S.-Y.; Hsieh, H.-P., Novel Indole-Based Peroxisome Proliferator-Activated Receptor Agonists: Design, SAR, Structural Biology, and Biological Activities. *Journal of Medicinal Chemistry* **2005**, 48, (26), 8194-8208.
245. Wang, P.-R.; Guo, Q.; Ippolito, M.; Wu, M.; Milot, D.; Ventre, J.; Doebber, T.; Wright, S. D.; Chao, Y.-S., High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. *European Journal of Pharmacology* **2001**, 427, (3), 285-293.
246. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V., Ligand binding and co-activator assembly

- of the peroxisome proliferator-activated receptor-[gamma]. *Nature* **1998**, 395, (6698), 137-143.
247. Pinelli, A.; Godio, C.; Laghezza, A.; Mitro, N.; Fracchiolla, G.; Tortorella, V.; Lavecchia, A.; Novellino, E.; Fruchart, J.-C.; Staels, B.; Crestani, M.; Liodice, F., Synthesis, Biological Evaluation, and Molecular Modeling Investigation of New Chiral Fibrates with PPAR α and PPAR γ Agonist Activity. *Journal of Medicinal Chemistry* **2005**, 48, (17), 5509-5519.
248. Koelsch, C. F., 6-BROMO-2-NAPHTHOL. *Organic Syntheses, Coll. Vol.* **1955**, 3, 132.
249. Meegalla, S. K.; Rodrigo, R., A general synthetic route to isobenzofurans bearing a functionalized C-1 substituent. *The Journal of Organic Chemistry* **1991**, 56, (5), 1882-1888.
250. Harabe, T.; Matsumoto, T.; Shioiri, T., Conformational analysis and selective hydrolysis of 2,5-disubstituted-1,3-dioxane-2-carboxylic acid esters. *Tetrahedron Letters* **2007**, 48, (8), 1443-1446.
251. Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D., Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures1. *The Journal of Organic Chemistry* **1996**, 61, (11), 3849-3862.